Peptide Receptor Radionuclide Therapy (PRRT) in Tumors With High Expression of Somatostatin Receptors (Phase 2) — FENET-2016  

Neuroendocrine Tumors Clinical Trial

Official title: Peptide Receptor Radionuclide Therapy (PRRT) in Tumors With High Expression of Somatostatin Receptors

Status Recruiting

Clinical Trial Summary

The rationale behind the purpose of this study lays on:

• the evidence that PRRT could represent a valuable treatment for the majority of patients with neuroendocrine tumor (NET) in disease progression, operated or inoperable, presenting lesions expressing somatostatin receptors and for which standard treatments are not already available;

• the current impossibility of acquiring on the market radiolabelled analogues of somatostatin used for PRRT with marketing authorisation;

• the need to collect a larger case history than in previous studies;

• the need to stratify the various histotypes based on the response obtained;

• the need to define new treatment schemes that guarantee the maximum efficacy and the lowest possible toxicity - with low cumulative (and per cycle) activities radiopharmaceutical and according to the concept of dose hyperfractionation - with a view to an optimal balance between risk and benefit.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Neuroendocrine Tumors
• Peptide Receptor Radionuclide Therapy (PRRT)

• NCT number: NCT04790708
• Study type: Interventional
• Source: University Hospital of Ferrara
• Contact: Mirco Bartolomei, MD
• Phone: 0532236082
• Email: m.bartolomei@ospfe.it
• Status: Recruiting
• Phase: N/A
• Start date: July 2, 2018
• Completion date: June 30, 2023